SLNO (Soleno Therapeutics Inc) Earnings per share for the last four quarters

Strong pricing power in the orphan drug segment allows Soleno Therapeutics (SLNO) to dictate payment terms, which is reflected in the historical percentage growth of EPS YoY (ttm), where the current metric equals 139.20. The business relies on an asset-light model with outsourced production, and its success is independent of economic cycles, basing itself exclusively on the clinical trial results of new drugs.
SLNO (Soleno Therapeutics): analytical breakdowns and indicator data

For Soleno Therapeutics (SLNO), which monetizes exclusivity in the treatment of Prader-Willi syndrome, this indicator measures the rate of change in net earnings per share over a rolling year, revealing hidden shifts in fundamental value. By analyzing the annual EPS TTM growth rate, an investor can assess the business's resilience to market volatility, recognizing that even an upward trend does not eliminate the risk of a sharp capital correction.